Long-acting controlled drug release formulations are highly desired for potentiating efficacy and reducing administration frequency.
Here we present a kinetically controllable long-term interleukin-2 (IL-2) release platform by the fusion and boundary elimination of calcium carbonate and calcium phosphate amorphous phases.
Unlike mixtures, a group of hybrid biominerals with the chemical formula Ca(CO
